Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors.

OBJECT Growth factors such as bone morphogenetic protein-2 (BMP-2) have been proven to promote spine fusion and to overcome the disadvantages of an autologous bone graft. The optimum method to deliver such growth factors remains a matter of discussion. The purpose of this study was to determine the safety and efficacy of a new poly(D,L-lactide) (PDLLA) carrier system for BMP-2 and to compare this carrier system with a collagen sponge carrier in a sheep cervical spine interbody fusion model. METHODS Thirty-two sheep underwent C3-4 discectomy and fusion: Group 1, titanium cage (eight animals); Group 2, titanium cage coated with a PDLLA carrier (eight animals); Group 3, titanium cage coated with a PDLLA carrier including BMP-2 (150 microg) (eight animals); and Group 4, titanium cage combined with a collagen sponge carrier including BMP-2 (150 microg) (eight animals). Blood samples, body weight, and temperature were assessed. Radiographs were obtained pre- and postoperatively and after 1, 2, 4, 8, and 12 weeks. At the same time points, disc space height, intervertebral angle, and lordosis angle were measured. After the sheep were killed 12 weeks postoperatively, flexion-extension radiography was performed to evaluate fusion sites. Quantitative computerized tomography scans were obtained to assess bone mineral density (BMD), bone mineral content (BMC), and bone callus volume (BCV). Biomechanical testing was performed in flexion, extension, axial rotation, and lateral bending. Stiffness, range of motion, neutral, and elastic zone were determined. Histomorphological and -morphometrical analyses were performed, and polychrome sequential labeling was used to determine the timeframe of new bone formation. There were no differences among the groups concerning blood counts, body weight, and temperature. Compared with the noncoated cages, all PDLLA-coated cages showed significantly higher values for BMD of the callus, as well as slightly higher values for BMC, BCV, and the bone volume/total volume ratio. In comparison with the cage-alone group, the BMP-2 groups showed significantly higher values for BMD and biomechanical stiffness. Histomorphological, -morphometrical, and polychrome sequential labeling analyses demonstrated greater progression of callus formation in the BMP-2 groups than in any other group. Compared with BMP-2 delivered using a collagen sponge carrier, BMP-2 application with a PDLLA carrier resulted in a higher BCV and a greater progression of interbody callus formation in the histomorphometrical analysis. CONCLUSIONS The use of cervical spine interbody fusion cages coated with PDLLA as a delivery system for growth factors was effective. In this 12-week follow-up study, the PDLLA coating showed no adverse effects. The slight but not significant positive effect of the PDLLA carrier on interbody fusion might be a result of the degradation process of the biodegradable carrier. Compared with collagen sponge delivery of BMP-2, the PDLLA-coated interbody cages significantly increased the results of interbody bone matrix formation. In this new combination (implant + PDLLA + growth factor) the cage represents a "real fusion" cage, because it not only serves as a mechanical device for spinal fixation but also as a local drug delivery system.

[1]  P. Törmälä,et al.  Absorption, biocompatibility, and fixation properties of polylactic acid in bone tissue: an experimental study in rats. , 1991, Clinical orthopaedics and related research.

[2]  R. Herrmann,et al.  Antithrombogenic Coating of Stents Using a Biodegradable Drug Delivery Technology , 1999, Thrombosis and Haemostasis.

[3]  J O Hollinger,et al.  Biodegradable bone repair materials. Synthetic polymers and ceramics. , 1986, Clinical orthopaedics and related research.

[4]  T. Mittlmeier,et al.  Biomechanical Assessment of Transoral Plate Fixation for Atlantoaxial Instability , 2000, Spine.

[5]  A. Göpferich,et al.  Mechanisms of polymer degradation and erosion. , 1996, Biomaterials.

[6]  J. Wozney,et al.  Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model. , 1997, Journal of spinal disorders.

[7]  T. Mittlmeier,et al.  Comparison Between Sheep and Human Cervical Spines: An Anatomic, Radiographic, Bone Mineral Density, and Biomechanical Study , 2001, Spine.

[8]  Y. Ikada,et al.  Effect of polylactic acid on osteoinduction of demineralized bone: preliminary study of the usefulness of polylactic acid as a carrier of bone morphogenetic protein. , 1994, Journal of oral rehabilitation.

[9]  J. Wozney,et al.  Bone Formation with Use of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2)* , 1997, The Journal of bone and joint surgery. American volume.

[10]  D. E. Cutright,et al.  Fracture reduction using a biodegradable material, polylactic acid. , 1971, Journal of oral surgery.

[11]  J M Brady,et al.  Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. , 1977, Journal of biomedical materials research.

[12]  M. Marone,et al.  Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. , 1999, Journal of spinal disorders.

[13]  J. Wozney,et al.  Safety of Recombinant Human Bone Morphogenetic Protein‐2 After Spinal Laminectomy in the Dog , 1999, Spine.

[14]  Y. Hashizume,et al.  Experimental chronic compression on the spinal cord of the rabbit by ectopic bone formation in the ligamentum flavum with bone morphogenetic protein , 1997, Spinal Cord.

[15]  M. Markel,et al.  Cervical Interbody Fusion Cages: An Animal Model With and Without Bone Morphogenetic Protein , 1998, Spine.

[16]  N. Endo,et al.  Local effects of transforming growth factor-β1 on rat calvaria: Changes depending on the dose and the injection site , 1999, Journal of Bone and Mineral Metabolism.

[17]  N P Haas,et al.  Biomechanical Comparison of Cervical Spine Interbody Fusion Cages , 2001, Spine.

[18]  F Leonard,et al.  Biodegradable poly(lactic acid) polymers. , 1971, Journal of biomedical materials research.

[19]  R Langer,et al.  Erosion kinetics of hydrolytically degradable polymers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Aspenberg,et al.  BMP-2 for intramuscular bone induction: effect in squirrel monkeys is dependent on implantation site. , 1996, Acta orthopaedica Scandinavica.

[21]  N. Amizuka,et al.  Fibroblasts of spinal ligaments pathologically differentiate into chondrocytes induced by recombinant human bone morphogenetic protein-2: morphological examinations for ossification of spinal ligaments. , 1997, Bone.

[22]  Cloward Rb The anterior surgical approach to the cervical spine: the cloward procedure: past, present, and future ― The presidential guest lecture, cervical spine research society , 1988 .

[23]  J. Ranchalis,et al.  Controlled release of TGF-β1 from a biodegradable matrix for bone regeneration , 1994 .

[24]  H. Schliephake,et al.  A review of material properties of biodegradable and bioresorbable polymers and devices for GTR and GBR applications. , 1996, The International journal of oral & maxillofacial implants.

[25]  J. Fischgrund,et al.  The Use of Recombinant Human Bone Morphogenetic Protein 2 (rhBMP‐2) to Promote Spinal Fusion in a Nonhuman Primate Anterior Interbody Fusion Model , 1999, Spine.

[26]  K. Takaoka,et al.  Telopeptide‐depleted bovine skin collagen as a carrier for bone morphogenetic protein , 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[27]  N P Haas,et al.  Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. , 2001, Journal of biomedical materials research.

[28]  H. Moriya,et al.  Bone Morphogenetic Protein-2 Stimulates Differentiation of Cultured Spinal Ligament Cells from Patients with Ossification of the Posterior Longitudinal Ligament , 1997, Calcified Tissue International.

[29]  N P Haas,et al.  Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-beta1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. , 2001, Bone.

[30]  S. Boden,et al.  The Use of rhBMP-2 in Interbody Fusion Cages: Definitive Evidence of Osteoinduction in Humans: A Preliminary Report , 2000, Spine.

[31]  O. Illi,et al.  Stimulation of fracture healing by local application of humoral factors integrated in biodegradable implants. , 1998, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

[32]  S. Boden,et al.  Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage , 1998 .

[33]  R. Delamarter,et al.  Effective Doses of Recombinant Human Bone Morphogenetic Protein‐2 in Experimental Spinal Fusion , 1996, Spine.

[34]  Fred Leonard,et al.  Polylactic Acid for Surgical Implants , 1966 .

[35]  P. Leung,et al.  Absorbable intramedullary implants for hand fractures. Animal experiments and clinical trial. , 1992, The Journal of bone and joint surgery. British volume.

[36]  S. Boden,et al.  Posterolateral Lumbar Intertransverse Process Spine Arthrodesis With Recombinant Human Bone Morphogenetic Protein 2/Hydroxyapatite‐Tricalcium Phosphate After Laminectomy in the Nonhuman Primate , 1999, Spine.

[37]  S. Merser,et al.  Rapid release of gentamicin from collagen sponge. In vitro comparison with plastic beads. , 1990, Acta orthopaedica Scandinavica.

[38]  P. Working,et al.  Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits. , 1993, International review of experimental pathology.

[39]  J. Wozney,et al.  Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers. , 1999, Spine.

[40]  P. Wilton Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. , 1992, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[41]  K. Takaoka,et al.  Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2. , 1999, Spine.

[42]  J M Brady,et al.  Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. , 1973, Journal of biomedical materials research.